Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38827 | 0.95 | MAPT (0.57) | MAPTL3MBTL1KMT2AMEN1HTT | |
| SCHEMBL28998051 | 0.94 | ALDH1A1 (0.59) | MAPTL3MBTL1KMT2AMEN1HTT | |
| SCHEMBL28998047 | 0.92 | ALDH1A1 (0.62) | MAPTL3MBTL1KMT2AMEN1HTT | |
| SCHEMBL1310780 | 0.89 | MAPT (0.60) | MAPTL3MBTL1KMT2AMEN1HTT | |
| SCHEMBL777891 | 0.89 | HRH1 (0.55) | MAPTL3MBTL1KMT2AMEN1HTT | |
| SCHEMBL20692823 | 0.89 | MAPT (0.52) | MAPTL3MBTL1KMT2AMEN1HTT | |
| SCHEMBL8973821 | 0.88 | HTT (0.63) | KMT2AMEN1HTTKDM4ENPSR1 | |
| Hydrochloric Acid SCHEMBL28628717 | 0.87 | POLB (0.54) | MAPTL3MBTL1KMT2AMEN1HTT | |
| Hydrochloric Acid SCHEMBL30475189 | 0.87 | POLB (0.54) | MAPTL3MBTL1KMT2AMEN1HTT | |
| SCHEMBL18383753 | 0.86 | MAPT (0.51) | MAPTL3MBTL1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823099-A | Preparation method of gedali plug | 浙江大学衢州研究院 | 2025-04-15 | — | — | CN | claimed |
| CN-118745169-A | Preparation method of 4- (4, 6-dimorphine-1, 3, 5-triazine-2-yl) aniline and intermediate thereof | 浙江大学衢州研究院 | 2024-10-08 | — | — | CN | claimed |
| CN-118745159-A | Preparation method of Gedatolisib key intermediate | 浙江大学衢州研究院 | 2024-10-08 | — | — | CN | claimed |
| CN-119823099-A | Preparation method of gedali plug | 浙江大学衢州研究院 | 2025-04-15 | — | — | CN | disclosed |
| CN-118745169-A | Preparation method of 4- (4, 6-dimorphine-1, 3, 5-triazine-2-yl) aniline and intermediate thereof | 浙江大学衢州研究院 | 2024-10-08 | — | — | CN | disclosed |
| CN-118745159-A | Preparation method of Gedatolisib key intermediate | 浙江大学衢州研究院 | 2024-10-08 | — | — | CN | disclosed |
| CN-118745159-A | Preparation method of Gedatolisib key intermediate | 浙江大学衢州研究院 | 2024-10-08 | — | — | CN | disclosed |
| WO-2024151953-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES CAUSED BY SARS-COV-2 AND OTHER CORONAVIRUSES | VIRADEM INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151953-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES CAUSED BY SARS-COV-2 AND OTHER CORONAVIRUSES | VIRADEM INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20060199804-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040116421-A1 | Heterocyclic compound and antitumor agent containing the same as active ingredient | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1389617-A1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-0629622-B1 | S-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5489591-A | INHIBITORS OF AROMATASE; TREATING ENDOMETRIOSIS, BREAST CANCER CYSTIC OVARIES | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-02-06 | — | — | US | disclosed |
| EP-0629622-A1 | s-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199804-A1 | Compounds | CA4, CA6, CYP2B6 | MAPT 4672/4885L3MBTL1 2640/4885KMT2A 4253/4885 |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MAPT 3737/4885L3MBTL1 312/4885KMT2A 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.